The Celgene/BMS PKCθ kinase inhibitor, CC-90005 , highlighted by Julien Lefranc , is a clinical candidate in Ph. I for psoriasis, [...]
< 1 minute read
Oct. 6, 2021
An Isoform-Selective PKCθ Kinase Inhibitor for Psoriasis
CC-90005
oral, selective PKCθ kinase inhibitor Ph. I candidate for Psoriasis from screen of internal library and SBDD Journal of Medicinal Chemistry Celgene/BMS, San Diego, CA, USA
Reviewer:
Loading...
